Pulmonary Hypertension Associated with Chronic Respiratory Disease

Clinics in Chest Medicine

Volumn 28, Issue 1, 2007, Pages 219-232

  Girgis, Reda E ^a   Mathai, Stephen C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EXERCISE TEST; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HISTIOCYTOSIS X; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS HYPOVENTILATION; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; LUNG WEDGE PRESSURE; LYMPHANGIOLEIOMYOMATOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; OXYGEN TENSION; OXYGEN THERAPY; PH; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SARCOIDOSIS; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING;

CHRONIC DISEASE; COMORBIDITY; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; NATRIURETIC PEPTIDE, BRAIN; OXYGEN INHALATION THERAPY; POSITIVE-PRESSURE RESPIRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY WEDGE PRESSURE; RESPIRATORY TRACT DISEASES; SLEEP APNEA SYNDROMES;

EID: 33847378507     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.11.006     Document Type: Review

References (100)

1. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 5S-12S
2. Hyduk A., Croft J.B., Ayala C., et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 54 5 (2005) 1-28
3. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 2 (2005) 189-194
4. Lettieri C.J., Nathan S.D., Barnett S.D., et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 3 (2006) 746-752
5. Leuchte H.H., Baumgartner R.A., Nounou M.E., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 173 7 (2006) 744-750
6. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 25 5 (2005) 783-788
7. Rubin L.J. Pulmonary arterial hypertension. Proc Am Thorac Soc 3 1 (2006) 111-115
8. Thabut G., Dauriat G., Stern J.B., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127 5 (2005) 1531-1536
9. Oswald-Mammosser M., Weitzenblum E., Quoix E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107 5 (1995) 1193-1198
10. Santos S., Peinado V.I., Ramirez J., et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur Respir J 19 4 (2002) 632-638
11. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part one. Am J Respir Crit Care Med 150 3 (1994) 833-852
12. Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A., et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 324 22 (1991) 1539-1547
13. Barbera J.A., Peinado V.I., Santos S., et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 164 4 (2001) 709-713
14. Clini E., Cremona G., Campana M., et al. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment. Am J Respir Crit Care Med 162 2 Pt 1 (2000) 446-450
15. Yildiz P., Oflaz H., Cine N., et al. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD. Respir Med 97 12 (2003) 1282-1288
16. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 2 (1992) 70-75
17. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 24 (1993) 1732-1739
18. Santos S., Peinado V.I., Ramirez J., et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 9 (2003) 1250-1256
19. Eddahibi S., Chaouat A., Morrell N., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108 15 (2003) 1839-1844
20. Barbera J.A., Peinado V.I., and Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21 5 (2003) 892-905
21. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 150 4 (1994) 1158-1168
22. Scharf S.M., Iqbal M., Keller C., et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166 3 (2002) 314-322
23. Shepard J.M., Gropper M.A., Nicolaysen G., et al. Lung microvascular pressure profile measured by micropuncture in anesthetized dogs. J Appl Physiol 64 2 (1988) 874-879
24. Harris P., Segel N., Green I., et al. The influence of the airways resistance and alveolar pressure on the pulmonary vascular resistance in chronic bronhcitis. Cardiovasc Res 2 1 (1968) 84-92
25. McGregor M., and Sniderman A. On pulmonary vascular resistance: the need for more precise definition. Am J Cardiol 55 1 (1985) 217-221
26. Naeije R., and Barbera J.A. Pulmonary hypertension associated with COPD. Crit Care 5 6 (2001) 286-289
27. Chang B., Wigley F.M., White B., et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30 11 (2003) 2398-2405
28. Leuchte H.H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170 4 (2004) 360-365
29. Agusti A.G., Roca J., Gea J., et al. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 143 2 (1991) 219-225
30. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128 4 (2005) 2393-2399
31. Heath D., and Smith P. Disorders of the vascular system. In: Thurlbeck W.M. (Ed). Pathology of the lung (1988), Thieme Medical Publishers, Stuttgart (Germany) 687-750
32. Ebina M., Shimizukawa M., Shibata N., et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169 11 (2004) 1203-1208
33. Weitzenblum E., Ehrhart M., Rasaholinjanahary J., et al. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 44 2 (1983) 118-127
34. Giaid A., Michel R.P., Stewart D.J., et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341 8860 (1993) 1550-1554
35. Trakada G., Nikolaou E., Pouli A., et al. Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 7 3 (2003) 111-118
36. Takemura T., Matsui Y., Saiki S., et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 23 11 (1992) 1216-1223
37. Handa T., Nagai S., Miki S., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129 5 (2006) 1246-1252
38. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61 1 (2006) 68-74
39. Sulica R., Teirstein A.S., Kakarla S., et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128 3 (2005) 1483-1489
40. Shorr A.F., Davies D.B., and Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124 3 (2003) 922-928
41. Arcasoy S.M., Christie J.D., Pochettino A., et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 120 3 (2001) 873-880
42. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 161 1 (2000) 216-223
43. Taveira-DaSilva A.M., Stylianou M.P., Hedin C.J., et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 168 12 (2003) 1427-1431
44. Niijima M., Kimura H., Edo H., et al. Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 159 6 (1999) 1766-1772
45. Schafer H., Hasper E., Ewig S., et al. Pulmonary haemodynamics in obstructive sleep apnoea: time course and associated factors. Eur Respir J 12 3 (1998) 679-684
46. Zielinski J. Effects of intermittent hypoxia on pulmonary haemodynamics: animal models versus studies in humans. Eur Respir J 25 1 (2005) 173-180
47. Atwood C.W., Jr., McCrory D., Garcia J.G., et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 72S-77S
48. Bady E., Achkar A., Pascal S., et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 55 11 (2000) 934-939
49. Chaouat A., Weitzenblum E., Krieger J., et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 109 2 (1996) 380-386
50. Kessler R., Chaouat A., Schinkewitch P., et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 120 2 (2001) 369-376
51. Sajkov D., Wang T., Saunders N.A., et al. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am J Respir Crit Care Med 159 5 Pt 1 (1999) 1518-1526
52. Shamsuzzaman A.S., Gersh B.J., and Somers V.K. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290 14 (2003) 1906-1914
53. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 19 (2000) 1378-1384
54. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 112 3 (2005) 375-383
55. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 27 9 (2006) 1106-1113
56. Sanner B.M., Doberauer C., Konermann M., et al. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 157 21 (1997) 2483-2487
57. Oswald-Mammosser M., Oswald T., Nyankiye E., et al. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 71 5 (1987) 419-429
58. Tan R.T., Kuzo R., Goodman L.R., et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest 113 5 (1998) 1250-1256
59. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 5 (2003) 735-740
60. Tramarin R., Torbicki A., Marchandise B., et al. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J 12 2 (1991) 103-111
61. Flaherty K.R., Andrei A.C., Murray S., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six minute hallwalk. Am J Respir Crit Care Med 174 7 (2006) 803-809
62. Naeije R. Pulmonary hypertension and right heart failure in COPD. Monaldi Arch Chest Dis 59 3 (2003) 250-253
63. Fletcher E.C., Luckett R.A., Miller T., et al. Exercise hemodynamics and gas exchange in patients with chronic obstruction pulmonary disease, sleep desaturation, and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 140 5 (1989) 1237-1245
64. Riley D.J. Risk of surgical lung biopsy in idiopathic interstitial pneumonias. Chest 127 5 (2005) 1485-1486
65. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 130 6 (1984) 993-998
66. Zielinski J., Tobiasz M., Hawrylkiewicz I., et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 113 1 (1998) 65-70
67. Crockett AJ, Cranston JM, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001;(3):CD002883.
68. Fletcher E.C., Donner C.F., Midgren B., et al. Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. Chest 101 3 (1992) 649-655
69. Fletcher E.C., Luckett R.A., Goodnight-White S., et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 145 5 (1992) 1070-1076
70. Chaouat A., Weitzenblum E., Kessler R., et al. Outcome of COPD patients with mild daytime hypoxaemia with or without sleep-related oxygen desaturation. Eur Respir J 17 5 (2001) 848-855
71. Fujimoto K., Matsuzawa Y., Yamaguchi S., et al. Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. Chest 122 2 (2002) 457-463
72. Alchanatis M., Tourkohoriti G., Kakouros S., et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 68 6 (2001) 566-572
73. Sajkov D., Wang T., Saunders N.A., et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165 2 (2002) 152-158
74. Valencia-Flores M., Orea A., Herrera M., et al. Effect of bariatric surgery on obstructive sleep apnea and hypopnea syndrome, electrocardiogram, and pulmonary arterial pressure. Obes Surg 14 6 (2004) 755-762
75. Schonhofer B., Barchfeld T., Wenzel M., et al. Long term effects of non-invasive mechanical ventilation on pulmonary haemodynamics in patients with chronic respiratory failure. Thorax 56 7 (2001) 524-528
76. Olson A.L., and Zwillich C. The obesity hypoventilation syndrome. Am J Med 118 9 (2005) 948-956
77. Aboussouan L.S., Khan S.U., Meeker D.P., et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 127 6 (1997) 450-453
78. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 2 (1999) 600-607
79. Gomez A., Bialostozky D., Zajarias A., et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 38 4 (2001) 1137-1142
80. Agostoni P., Doria E., Galli C., et al. Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 139 1 (1989) 120-125
81. Melot C., Hallemans R., Naeije R., et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 130 4 (1984) 612-616
82. Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc 2 1 (2005) 12-19
83. Maloney J.P. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 9 2 (2003) 139-143
84. Archer S.L., Mike D., Crow J., et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 109 3 (1996) 750-755
85. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 9337 (2002) 895-900
86. Strange C., Bolster M., Mazur J., et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 118 4 (2000) 1077-1082
87. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 9 (1999) 740-743
88. Walmrath D., Schneider T., Pilch J., et al. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 151 3 Pt 1 (1995) 724-730
89. Tissieres P., Nicod L., Barazzone-Argiroffo C., et al. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann Thorac Surg 78 3 (2004) e48-e50
90. Foley R.J., and Metersky M.L. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration (2005) [Epub ahead of print]
91. Clozel M., and Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 37 1 (2005) 2-12
92. ATS presentation highlights strong rationale for a morbidity/mortality study with bosentan in Idiopathic Pulmonary Fibrosis (IPF). Allschwil, Switzerland: Actelion, May 23, 2006 [press release].
93. Krasuski R.A., Warner J.J., Wang A., et al. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36 7 (2000) 2204-2211
94. Barbera J.A., Roger N., Roca J., et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 347 8999 (1996) 436-440
95. Vonbank K., Ziesche R., Higenbottam T.W., et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 58 4 (2003) 289-293
96. Yung G.L., Kriett J.M., Jamieson S.W., et al. Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation. J Heart Lung Transplant 20 11 (2001) 1224-1227
97. Preston I.R., Klinger J.R., Landzberg M.J., et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120 3 (2001) 866-872
98. Alp S., Skrygan M., Schmidt W.E., et al. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 19 6 (2006) 386-390
99. Madden B.P., Allenby M., Loke T.K., et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44 5 (2006) 372-376
100. Egan T.M., Murray S., Bustami R.T., et al. Development of the new lung allocation system in the United States. Am J Transplant 6 5 Pt 2 (2006) 1212-1227